McKinsey's research on AI in biopharma has identified a clear correlation between platform maturity and AI impact: organisations that have invested in shared AI infrastructure report two to five times the return on AI investment compared to organisations pursuing project-by-project approaches. [1] The distinction this finding rests on, between an AI point solution that solves a single problem and an AI platform that provides the shared data, compute, tooling, and governance enabling many applications to be developed and maintained efficiently, is the most important architectural decision a pharma organisation makes when investing in AI.
At Pienomial, we built KnolForge as the enterprise AI platform infrastructure layer of Knolens specifically because we understood this platform effect early: every new AI application built on a shared foundation benefits from the data integration, governance frameworks, and organisational learning that previous applications already established, creating compounding returns that a collection of disconnected point solutions can never achieve. [1] This post explains what genuinely constitutes an enterprise AI platform for pharma, why the architecture decision matters more than any individual AI feature, and how KnolForge delivers this foundation as part of the broader trusted enterprise AI that Knolens provides.[9]
A point solution addresses a single, well-defined problem: predicting protein structure, optimising a clinical trial design, or identifying adverse events in safety reports. Point solutions are valuable and often produce strong results for the specific task they were built for. The limitation is structural: each point solution typically requires its own data integration effort, its own governance configuration, and its own infrastructure investment, none of which transfers to the next point solution the organisation deploys.[1]
An enterprise AI platform inverts this model. It provides the shared data, compute, tooling, and governance layer that enables many applications to be developed, deployed, and maintained on common infrastructure. The platform effect this creates is compounding: each new application benefits from the data integration, security controls, and organisational learning accumulated by every application that came before it, rather than starting from zero. [1] This is the architectural principle that explains McKinsey's two-to-five-times ROI finding: it is not that platform-based AI is inherently more accurate than point solutions, it is that the cost of deploying the third, fourth, and tenth AI application on a shared platform is a fraction of the cost of building each as an isolated point solution.
Treating AI as infrastructure rather than as a collection of individual projects changes how an organisation budgets, governs, and staffs its AI programme. Infrastructure investments are evaluated on their capacity to enable future value creation, not solely on the returns from the current application being built, which is a longer-term investment perspective that most pharma procurement processes are not naturally structured to apply.[1]
This infrastructure mindset shift has practical implications for how pharma CTOs and Chief Data Officers should evaluate an enterprise AI platform investment. A point solution procurement decision asks: does this tool solve our immediate problem at an acceptable cost? A platform procurement decision asks: does this infrastructure reduce the marginal cost of every future AI application we will need to deploy across HEOR, regulatory, competitive intelligence, and clinical functions over the next three to five years? The second question requires a fundamentally different evaluation framework, one that weighs compounding organisational capability rather than isolated feature comparison.[4]
A genuine enterprise AI platform for pharma requires five distinct architectural layers, each providing infrastructure that subsequent AI applications can build on rather than rebuild.[9]
Layer 1, Governed knowledge foundation: A validated, continuously updated knowledge graph containing clinical, regulatory, HTA, competitive, and commercial intelligence, with domain ontologies, source validation, and claim-level attribution built in. Every application built on the platform, whether a research tool, an authoring tool, or an expert simulation tool, draws from this same governed foundation rather than maintaining separate, inconsistent data sources.
Layer 2, Compute and inference infrastructure: The LLM-agnostic inference layer that generates natural language outputs from retrieved facts, deployable across cloud, private cloud, and on-premise environments depending on data sensitivity requirements. This layer is shared across every application: the same inference infrastructure that powers a HEOR evidence synthesis tool also powers a competitive intelligence alerting tool, without each requiring separate infrastructure procurement.[2]
Layer 3, Governance and compliance framework: Role-based access controls, audit trail logging, output classification by risk tier, and human review workflow infrastructure that satisfies GxP, FDA 21 CFR Part 11, and EU AI Act requirements. This layer is configured once at the platform level and inherited by every application built on top of it, rather than requiring each new AI tool to build its own compliance infrastructure from scratch.[6]
Layer 4, Workflow and orchestration tooling: The shared tooling that enables specific applications, research workflows, authoring workflows, expert simulation workflows, and agentic multi-step workflows, to be configured and deployed on the platform without bespoke software development for each new use case. This is what allows a pharma organisation to deploy a new AI application for a new therapeutic area or function in weeks rather than months.
Layer 5, Organisational learning and institutional memory: The accumulated knowledge, validated relationships, and refined workflows that the platform retains across every project conducted on it. Unlike a point solution, where institutional knowledge is lost when the project ends or the team member who built it moves on, the platform layer preserves this learning structurally, available to every future application and every future team member.[1]
Gartner predicts that 60% of agentic AI projects will fail in 2026 due to a lack of AI-ready data, and that unless data maturity reaches a minimum viable threshold, AI models deliver inaccurate insights or fail outright. [5] This finding underscores why the governed knowledge foundation layer of an enterprise AI platform is not an optional architectural nicety. It is the layer that determines whether every subsequent application built on the platform succeeds or fails.
Infrastructure readiness, covering modern, scalable cloud environments, data platforms, MLOps pipelines, monitoring systems, and security layers, must be established before AI deployment at scale, not retrofitted after a point solution has already demonstrated value in a pilot. [5] Pharma organisations that deploy a successful AI pilot and then attempt to scale it across the organisation frequently discover that the data infrastructure underlying the pilot does not generalise to the broader organisational data landscape, requiring costly reengineering during what should have been a straightforward scaling exercise.
This is precisely the failure mode that a genuine enterprise AI platform architecture prevents. Because the governed knowledge foundation is built as shared infrastructure from the outset, with domain ontologies, validated source ingestion, and claim-level attribution established at the platform level, every new application that draws on this foundation inherits AI-ready data by construction, rather than each application needing to solve the data readiness problem independently.[9]
5. Cloud, On-Premise, and Hybrid: The Deployment Flexibility Requirement
Pharma AI infrastructure in 2026 is converging on a hybrid deployment model: even organisations that emphasise on-premise expansion for their most sensitive data and compute still use a mix of on-premise and cloud infrastructure, keeping precious intellectual property and heavy compute in-house while bursting to the cloud for peak loads and less sensitive workloads. [2] This hybrid reality means a genuine enterprise AI platform must support deployment flexibility as a core architectural property, not as a bolt-on enterprise tier.
KnolForge is built on exactly this hybrid principle within the Knolens architecture: the same governed knowledge foundation and inference infrastructure can be deployed in public cloud, private cloud, or fully on-premise and air-gapped configurations depending on the data classification of the specific application. A HEOR team running competitive intelligence on public clinical trial data can operate in a standard cloud deployment, while a regulatory team processing unpublished trial results for the same organisation operates the identical platform capability within an on-premise deployment, with no functional capability lost by choosing the more secure deployment option.[9]
The EU AI Act, expected to classify many healthcare AI systems as high-risk, will require mandatory risk management, technical documentation, and conformity assessment, potentially involving third-party auditors, with compliance costs estimated at around 12% of development cost. [6] For a pharma organisation building AI applications as isolated point solutions, this compliance burden must be addressed separately for every single application, multiplying the total compliance investment across the organisation's AI portfolio.
For a pharma organisation built on a genuine enterprise AI platform, the governance and compliance framework, audit trail logging, access controls, risk classification, and conformity documentation, is established once at the platform layer and inherited automatically by every application built on top of it. This is not merely cost efficiency. It is a compliance reliability advantage: a platform-level governance framework, validated once and applied consistently, is more defensible under regulatory scrutiny than a patchwork of inconsistent governance implementations across a portfolio of point solutions built by different teams at different times.[8]
The practical demonstration of the enterprise AI platform principle within Knolens is the relationship between KnolForge and the other three Knolens products: KnolAI, KnolComposer, and KnolPersona. Each is a distinct application serving a distinct workflow, research intelligence, authoring, and expert simulation respectively, but all three are built on the same KnolForge platform foundation: the same governed knowledge graph, the same inference infrastructure, the same governance and compliance framework, and the same deployment flexibility.[9]
This shared foundation is what allows a HEOR team to use KnolAI for evidence synthesis, a regulatory team to use KnolComposer for dossier authoring, and a market access team to use KnolPersona for assessor challenge simulation, all working from a single consistent knowledge base with guaranteed factual consistency across every output, rather than each team operating a separate AI tool with separate, potentially inconsistent underlying data. When a new validated fact enters the Knolens knowledge graph through any application, it becomes available to every other application instantly, exactly the compounding platform effect that McKinsey's research identified as the source of superior AI ROI in biopharma.[1]
For pharma CTOs and Chief Data Officers evaluating an enterprise AI platform vendor, five questions distinguish a genuine platform architecture from a point solution marketed with platform language.[7]
Question 1, Does a new use case require new data integration, or does it draw on existing platform infrastructure? A genuine platform answer: new applications configure against the existing governed knowledge foundation. A point solution answer: each new use case requires its own data pipeline.
Question 2, Is governance configured once at the platform level, or per application? Platform-level governance, access controls, audit trails, and compliance documentation established once and inherited by every application, is the defining signature of genuine platform architecture.
Question 3, Does institutional knowledge persist across applications, or is each application's output isolated? A platform accumulates validated knowledge that every future application can draw on. A point solution's outputs typically remain isolated to that specific tool.
Question 4, Can the platform be deployed flexibly across cloud, private cloud, and on-premise without functional compromise? Deployment flexibility built into the core architecture, not offered as a constrained enterprise tier, indicates genuine platform design.[2]
Question 5, What is the marginal cost of the organisation's fifth AI use case compared to its first? On a genuine platform, the marginal cost should decline substantially because shared infrastructure absorbs most of the cost. On a collection of point solutions, the marginal cost remains roughly constant because each new use case starts from zero.[9]
Deploying KnolForge as your organisation's enterprise AI platform foundation does not require a multi-year infrastructure build before any application delivers value. KnolForge ships as a pre-built platform with the governed knowledge foundation, inference infrastructure, and governance framework already established, configurable to your organisation's data and compliance requirements from the first sprint.[9]
Sprint 1, Weeks 1 to 2, Platform foundation live with first application: KnolForge's governed knowledge foundation is connected to your indication scope and primary data sources. The first application, typically KnolAI for research intelligence, is deployed on the live platform foundation. Your team sees the platform principle in action immediately: the knowledge layer that powers this first application is the same layer every subsequent application will draw on.
Sprint 2, Weeks 3 to 4, Governance framework and deployment configuration: Access controls, audit trail logging, risk classification tiers, and the compliance documentation framework are configured at the platform level. Deployment configuration, cloud, private cloud, or on-premise, is established based on your data classification requirements, applying consistently across every current and future application.
Sprint 3, Weeks 5 to 6, Second application deployed on existing foundation: A second application, such as KnolComposer for dossier authoring or KnolPersona for expert simulation, is deployed on the existing KnolForge foundation. No new data integration or governance configuration is required: the second application inherits everything established in Sprints 1 and 2. The marginal deployment time for this second application is a fraction of the first, demonstrating the platform effect directly.[1]
Conclusion
The choice between AI point solutions and a genuine enterprise AI platform is the single most consequential architectural decision a pharma organisation makes in its AI strategy, and the evidence is increasingly clear: organisations investing in shared AI infrastructure achieve two to five times the return of those pursuing AI project by project. The compounding value of a platform, where every new application inherits the data integration, governance, and institutional learning of every application before it, is not available to organisations that treat each AI initiative as an isolated procurement decision.
At Pienomial, we built KnolForge as the enterprise AI platform foundation of Knolens precisely because we understood that pharma organisations do not need one more point solution. They need the infrastructure that makes every future AI application faster, cheaper, and more reliable to deploy than the one before it. That is what a genuine enterprise AI platform delivers, and that is what KnolForge is built to be. [9] CTA: See how KnolForge delivers compounding AI platform value for your organisation. Book a demo with the Pienomial team.
